Miranda VJE, Delgado GWP

Language: Spanish
References: 12
Page: 91-94
PDF size: 77.10 Kb.

ABSTRACT

The degenerative of the temporomandibular joint intraarticular tissues theory mention that the meniscus anterior displacement is thought to be due to the action of the lateral pterygoid muscle which stabilizes and controls the disk movements. In abnormal functions the excessive action or hyperactivity of the superior portion of the lateral pterygoid muscle makes the meniscus to displace anteriorly in cases with previous damage on it. The botullinum toxin type A (BTX-A) is a presynaptic neurotoxin which causes skeletal muscle paralysis produced by the presympathetic system, inhibing the acetylcholine. Directly applied to the lateral pterygoid muscle during the temporomandibular joint arthroscopy we will limit the anterior disk displacement. He did research for innovative technology for direct application of botulinum toxin type A in the upper portion of the lateral pterygoid muscles during temporomandibular joint arthroscopy in a selected sample of 60 joints of 30 patients with TMJ internal degeneration with anterior displacement of the articular disc with bilateral reduction in pain symptoms unresponsive to conservative treatment in population of the Hospital Regional «General Ignacio Zaragoza» Institute of Social Security and Services for State Employees, the area east of the city of Mexico City, during the period January 2006 to August 2008, after conservative treatment for three months. Getting excellent results in limiting the displacement of the articular disc and elimination of pain symptoms in all patients during clinical control at 3, 6 months to a year. Concluding that the application of botulinum toxin for therapeutic arthroscopy is an ideal complement to stabilize and control anterior displacement with reduction of the TMJ articular disc, eliminating the crack and the pain symptoms.

REFERENCES

1. Chris DN. A lateral pterygoid muscle and its relationship to the meniscus of the temporomandibular joint. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology & Endodontics 1996; 82 (1): 4-9.

2. Lowe NJ, Yamauchi P, Moore D. Journal of the American Academy of Dermatology. Medicina Estética, comparación aleatorizada, doble ciego, de tres dosis de toxina botulínica tipo A y placebo, en pacientes con patas de gallo. 2002; 47 (6): 834-840.

3. Revista de la Sociedad Española del Dolor, E:otoxuso de la toxina botulínica- V Reunión (2001).htm, 2001.

4. Rozalén, Lanzas, Verduras, Cuadra, Castillo. Sociedad Centro de Rehabilitación y Medicina Física. Uso de Toxina Botulínica en Rehabilitación: Espasticidad y Dolor Miofascial. Madrid, España, 2003.

5. Rai B, Anand SC. The Internet Journal of Academic Physician Assistants ISSN: 1092-4078. 2007.

6. Lowe NJ, Yamauchi P, Moore D. Journal of the American Academy of Dermatology. Medicina Estética, comparación aleatorizada, doble ciego de tres dosis de toxina botulínica tipo A y placebo, en pacientes con patas de gallo. 2002; 47 (6): 834-840.

7. Rosensrein SE. Diccionario de especialidades farmacéuticas 50 ed. 2004.

8. Ferrante FM. Las neurotoxinas en el tratamiento del dolor muscular. Los Ángeles, California, 2004.

9. Sabaté MC, Enríquez E, Sabaté M, Ramírez AC, Abreu JM. La toxina botulínica. Aplicación en Parálisis Cerebral. BSCP Can Ped 2002: 26(2-3).

10. Muñoz NT. Revista caretas. 2004. Ed. 1838, 2004. www.caretas.com.pe. La Jeringa de la Juventud. Toxina botulínica: el método más requerido para eliminar las arrugas en tiempo récord.

11. Freud BJ, Schwartz M. Intramuscular injection of botulinum toxin as an adjunct in arthrocentesis of the temporomandibular joint: Preliminary observations. British Journal of Oral and Maxillofacial Surgery 2003: 41 (12).

12. Ziegler C, Haag C, Muhling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Invest 2003.